

PRODUCT INFORMATION



Edoxaban-d₆ Item No. 25760

CAS Registry No.: 1304701-57-2
Formal Name: N¹-(5-chloro-2-pyridinyl)-N²-[(1S,2R,4S)-4-[[di(methyl-d₃)amino]carbonyl]-2-[[[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]cyclohexyl]-ethanediamide

MF: C₂₄H₂₄ClD₆N₇O₄S

FW: 554.1

Chemical Purity: ≥98% (Edoxaban)


Deuterium

Incorporation: ≥99% deuterated forms (d₁-d₆); ≤1% d₀

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Edoxaban-d₆ is intended for use as an internal standard for the quantification of edoxaban (Item No. 24030) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Edoxaban-d₆ is supplied as a solid. A stock solution may be made by dissolving the edoxaban-d₆ in the solvent of choice, which should be purged with an inert gas. Edoxaban-d₆ is soluble in organic solvents such as methanol and DMSO.

Description

Edoxaban is an orally bioavailable and potent inhibitor of factor Xa (K_is = 0.561 and 0.903 nM for free and complexed human factor Xa, respectively).¹ It is >10,000-fold selective for factor Xa over thrombin, FVIIa/sTF, FXIa, tPA, aPC, trypsin, plasmin, and chymotrypsin. Edoxaban prolongs prothrombin, activated partial thromboplastin, and thrombin clotting times in a concentration-dependent manner *ex vivo* in human plasma. Oral administration of edoxaban (0.5-12.5 mg/kg) reduces thrombus formation and prolongs prothrombin time in a dose-dependent manner in rat and rabbit models of venous stasis thrombosis. It also reduces thrombus formation in a rat model of platinum wire-induced venous thrombosis. Formulations containing edoxaban have been used to prevent stroke in patients with atrial fibrillation.

Reference

1. Furugohri, T., Isobe, K., Honda, Y., *et al.* DU-176b, a potent and orally active factor Xa inhibitor: *In vitro* and *in vivo* pharmacological profiles. *J. Thromb. Haemost.* **6**(9), 1542-1549 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/09/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM